Select Page

NEW YORK, Oct. 03, 2020 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceutical, Inc.  (“BioMarin” or the “Company”) (NASDAQ: BMRN) and certain of its officers.   The class action, filed in United States District Court for the Northern District of California, and docketed under 20-cv-06719, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired BioMarin securities between February 28, 2020 and August 18, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.